On June 29, Novel Medical held a product launch event in Chengdu to officially introduce its self-developed Insight 4D Quantitative SPECT/CT. The event was attended by many industry leaders and experts, including Professor Li Sijin, former President of Shanxi Medical University and former Chairman of the Chinese Society of Nuclear Medicine; Mr. Yang Dazhu, former Deputy Director General of the International Atomic Energy Agency; Mr. Gao Keli, Secretary General of the Chinese Nuclear Society; Professor Zhang Yongxue, former Chairman of the Nuclear Medicine Branch of the Chinese Nuclear Society; Mr. He Zuoxiang, Chairman of the Medical Physics Branch of the Chinese Nuclear Society; and Dr. Liu Yaqiang, Director of the Institute of Medical Physics, Department of Engineering Physics, Tsinghua University.
Since its establishment in 2011, Novel Medical has been dedicated to promoting the industrialization of excellent scientific research achievements from well-known universities in China, continuously advancing in the field of domestic alternatives. The newly launched Insight 4D Quantitative SPECT/CT is the culmination of years of technical accumulation and innovative practice by Novel Medical. Its overall performance indicators have reached international advanced levels, successfully filling a domestic gap.
At the launch event, Mr. Liu Mai, Chairman of Novel Medical, enthusiastically stated, "This brand-new domestic SPECT/CT product will make a significant contribution to the development of nuclear medicine in China, helping to improve the accuracy of disease diagnosis and treatment, and providing strong support for the equipment renewal and upgrade of medical institutions."
Jiang Nianming, R&D Director of Novel Medical, introduced the features of the Insight 4D Quantitative SPECT/CT. The series boasts outstanding performance, meeting the diverse imaging needs of nuclear medicine departments. Its SUV quantitative platform, supported by high-definition quantitative reconstruction and SUV quantitative analysis technologies, provides robust data support for precise lesion diagnosis. The cardiac 4D quantitative diagnostic platform offers high-definition, rapid imaging capabilities, especially for dynamic cardiac blood flow data, providing doctors with more accurate and comprehensive diagnostic information. Its intelligent and user-friendly design also enhances the overall user experience.
Dr. Huo Li, Director of the Nuclear Medicine Department at Peking Union Medical College Hospital, shared the outstanding performance of Insight in clinical trials and research applications. He highly praised Insight's exceptional capabilities and expressed eager anticipation for its widespread clinical use.
During the launch ceremony, the attending leaders and guests jointly activated the release device, marking the official launch of the Insight 4D Quantitative SPECT/CT. This brilliant moment represents a significant milestone in advancing the industry.
Looking ahead, Novel Medical will continue to delve deeply into the field of nuclear medicine technology, increasing investment in research and development, and promoting continuous innovation and upgrades of its products. The company is committed to achieving the goal of "making everyone's life safer and healthier" and looks forward to collaborating with more industry experts, medical institutions, and partners to jointly promote the flourishing development of nuclear medicine.
Language
